Citigroup’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-90,172
| Closed | -$274K | – | 6090 |
|
|
2024
Q4 | $274K | Buy |
90,172
+13,121
| +17% | +$57.2K | ﹤0.01% | 4207 |
|
|
2024
Q3 | $400K | Buy |
77,051
+52,132
| +209% | +$259K | ﹤0.01% | 3870 |
|
|
2024
Q2 | $64K | Sell |
24,919
-35,592
| -59% | -$122K | ﹤0.01% | 4450 |
|
|
2024
Q1 | $298K | Sell |
60,511
-30,777
| -34% | -$182K | ﹤0.01% | 3840 |
|
|
2023
Q4 | $802K | Buy |
91,288
+42,063
| +85% | +$345K | ﹤0.01% | 3025 |
|
|
2023
Q3 | $565K | Buy |
49,225
+10,517
| +27% | +$202K | ﹤0.01% | 2970 |
|
|
2023
Q2 | $980K | Buy |
38,708
+26,748
| +224% | +$833K | ﹤0.01% | 2858 |
|
|
2023
Q1 | $385K | Sell |
11,960
-28,908
| -71% | -$901K | ﹤0.01% | 3309 |
|
|
2022
Q4 | $754K | Sell |
40,868
-30,389
| -43% | -$695K | ﹤0.01% | 2872 |
|
|
2022
Q3 | $1.92M | Buy |
71,257
+46,925
| +193% | +$952K | ﹤0.01% | 2167 |
|
|
2022
Q2 | $336K | Buy |
24,332
+11,881
| +95% | +$183K | ﹤0.01% | 3531 |
|
|
2022
Q1 | $243K | Sell |
12,451
-17,759
| -59% | -$269K | ﹤0.01% | 3972 |
|
|
2021
Q4 | $493K | Buy |
30,210
+1,897
| +7% | +$31.6K | ﹤0.01% | 3803 |
|
|
2021
Q3 | $789K | Buy |
28,313
+15,095
| +114% | +$431K | ﹤0.01% | 3270 |
|
|
2021
Q2 | $392K | Buy |
13,218
+3,501
| +36% | +$101K | ﹤0.01% | 3860 |
|
|
2021
Q1 | $271K | Sell |
9,717
-10,058
| -51% | -$278K | ﹤0.01% | 3837 |
|
|
2020
Q4 | $561K | Buy |
19,775
+8,571
| +76% | +$222K | ﹤0.01% | 4101 |
|
|
2020
Q3 | $281K | Sell |
11,204
-14,532
| -56% | -$381K | ﹤0.01% | 4340 |
|
|
2020
Q2 | $629K | Buy |
25,736
+4,624
| +22% | +$91.3K | ﹤0.01% | 4020 |
|
|
2020
Q1 | $313K | Buy |
21,112
+5,830
| +38% | +$121K | ﹤0.01% | 4318 |
|
|
2019
Q4 | $248K | Sell |
15,282
-11,657
| -43% | -$181K | ﹤0.01% | 5004 |
|
|
2019
Q3 | $350K | Buy |
26,939
+1,118
| +4% | +$13.7K | ﹤0.01% | 4668 |
|
|
2019
Q2 | $335K | Sell |
25,821
-1,016
| -4% | -$12.8K | ﹤0.01% | 4825 |
|
|
2019
Q1 | $423K | Buy |
26,837
+6,729
| +33% | +$117K | ﹤0.01% | 4356 |
|
|
2018
Q4 | $405K | Buy |
20,108
+11,532
| +134% | +$254K | ﹤0.01% | 4356 |
|
|
2018
Q3 | $213K | Buy |
8,576
+8,369
| +4,043% | +$228K | ﹤0.01% | 5186 |
|
|
2018
Q2 | $6K | Sell |
207
-137
| -40% | -$4.12K | ﹤0.01% | 7320 |
|
|
2018
Q1 | $11K | Sell |
344
-60
| -15% | -$1.93K | ﹤0.01% | 7028 |
|
|
2017
Q4 | $14K | Buy |
404
+127
| +46% | +$3.65K | ﹤0.01% | 6902 |
|
|
2017
Q3 | $8K | Buy |
277
+37
| +15% | +$897 | ﹤0.01% | 6761 |
|
|
2017
Q2 | $6K | Sell |
240
-73
| -23% | -$1.63K | ﹤0.01% | 6713 |
|
|
2017
Q1 | $7K | Buy |
313
+44
| +16% | +$904 | ﹤0.01% | 6703 |
|
|
2016
Q4 | $6K | Hold |
269
| – | – | ﹤0.01% | 6886 |
|
|
2016
Q3 | $4K | Sell |
269
-6,089
| -96% | -$88.4K | ﹤0.01% | 6833 |
|
|
2016
Q2 | $86K | Sell |
6,358
-6,413
| -50% | -$113K | ﹤0.01% | 5203 |
|
|
2016
Q1 | $223K | Buy |
12,771
+2,115
| +20% | +$43K | ﹤0.01% | 4984 |
|
|
2015
Q4 | $364K | Buy |
10,656
+10,647
| +118,300% | +$369K | ﹤0.01% | 4196 |
|
|
2015
Q3 | $0 | Sell |
9
-3,295
| -100% | -$100K | ﹤0.01% | 7772 |
|
|
2015
Q2 | $106K | Sell |
3,304
-1,434
| -30% | -$36.9K | ﹤0.01% | 4952 |
|
|
2015
Q1 | $98K | Sell |
4,738
-3,102
| -40% | -$53.6K | ﹤0.01% | 5042 |
|
|
2014
Q4 | $133K | Buy |
7,840
+7,540
| +2,513% | +$132K | ﹤0.01% | 5017 |
|
|
2014
Q3 | $6K | Buy |
300
+242
| +417% | +$6.31K | ﹤0.01% | 6512 |
|
|
2014
Q2 | $2K | Sell |
58
-1,051
| -95% | -$32.9K | ﹤0.01% | 6786 |
|
|
2014
Q1 | $35K | Buy |
+1,109
| New | +$34.6K | ﹤0.01% | 5722 |
|
Other funds holding RVNC
Citigroup's RVNC Position: Q1 2025 in Review
Citigroup sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 90,172 shares — an estimated $274K sold.
Citigroup first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $1.92M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Citigroup reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Citigroup sold 90,172 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $274K.
- Citigroup first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Citigroup's Revance Therapeutics, Inc. position peaked at $1.92M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.